We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lung cancer 2008
- US incidence of NSCLC by stage (2003)
- ECOG 1594 study
- ECOG 1594 survival curve
- Selected trials of novel agents + chemotherapy
- ECOG 4599 study: Chemotherapy +/- bevacizumab
- Bevacizumab - structure
- Vascular endothelial growth factor
- The VEGF family
- Principles of angiogenesis
- Bevacizumab in NSCLC - ECOG 4599 (1)
- Bevacizumab in NSCLC: not for everybody
- Phase II trial of PC with/without bevacizumab
- PC +/- bevacizumab in metastatic NSCLC
- Bevacizumab in NSCLC - Hemorrhagic events
- Example of tumor cavitation following bevacizumab
- PC +/- bevacizumab - non-squamous subset
- Bevacizumab in NSCLC - ECOG 4599 (2)
- Patient characteristics
- Response rates
- Progression-free survival by Tx arm
- Survival by treatment arm
- Hematologic toxicity
- Non-hematologic toxicity
- Treatment related deaths
- Risk factors associated with bevacizumab
- E4599: efficacy by gender
- E4599: efficacy by age
- Toxicity on PCB arm - elderly vs. non-elderly
- NCCN practice guidelines in oncology
- AVAiL: phase III trial of bevacizumab + GC
- The AVAiL study: objectives
- The AVAiL study: eligibility
- The AVAiL study: patient accrual
- The AVAiL study: demographics
- Progression-free survival: primary analysis (1)
- Progression-free survival: primary analysis (2)
- PFS in subgroups of interest
- Overall response
- AVAiL: toxicity
- AVAiL: conclusions
- PCB in frontline metastatic NSCLC
- Bevacizumab in second line therapy
- Bevacizumab + chemo/erlotinib: RP2
- Efficacy and safety summary
- Progression-free survival
- Adjuvant therapy in NSCLC
- Lung adjuvant cisplatin evaluation
- OS by trial
- Survival curves
- E1505: phase III trial of adjuvant +/- bevacizumab
- Broader range safely treated with bevacizumab?
- The PASSPORT and ATLAS studies
- Brain metastases in pts receiving bevacizumab (1)
- Brain metastases in pts receiving bevacizumab (2)
- Brain metastases in pts receiving bevacizumab (3)
- Bevacizumab and full dose anti-coagulation
- AVAiL and FDAC
- AVAiL and FDAC: conclusions
- Protocol AVF3744g: BRIDGE trial
- Primary objective
- Schema of the BRIDGE study
- Bevacizumab in small cell lung cancer
- Bevacizumab in first-line extensive stage small cell
- Efficacy results
- Toxicity results
- Conclusions for chemo with bevacizumab
- Other VEGF inhibitors
- VEGFR TKI's
- Why when we have bevacizumab?
- Tyrosine kinases within the kinome
- Signaling pathways as targets in cancer
- Promising small molecule inhibitors of VEGFR
- Sorafenib
- Sorafenib phase II
- Sorafenib "window of opportunity" study
- Sorafenib and chemo: phase I subset analysis
- ESCAPE - phase III trial, CGl +/- sorafenib
- Overall survival by histology
- Sunitinib
- Sunitinib phase II
- Sunitinib: continuous dosing
- Vandetanib (ZD6474)
- Activity of dual VEGF/EGFR inhibition
- ZD6474 vs. gefitinib (1)
- Progression-free survival (1)
- ZD6474 vs. gefitinib (2)
- Docetaxel +/- ZD6474: phase II study design
- Progression-free survival (2)
- Docetaxel +/- ZD6474 in refractory NSCLC
- Vandetanib with or without CP for first-line NSCLC
- Progression-free survival (3)
- Exploratory analysis of PFS - gender
- Ongoing phase III trials of vandetanib
- Planned phase III trials for vandetanib
- Axitinib
- Axitinib: phase II
- Axitinib: results
- Vatalanib
- Toxicity of small molecular agents
- VEGFR TKIs and toxicity
- Efficacy comparison for antiangiogenic agents
- VEGFR TKIs: conclusions
- FLEX: a phase III study of cetuximab with CV
- FLEX : study design
- FLEX - RR, PFS, TTF
- FLEX overall survival
- Overall survival - subset analyses
- Cetuximab or bevacizumab?
- Bevacizumab: conclusions
- Thank you
Topics Covered
- Lung cancer incidence
- Survival by treatment group
- Selected trials of novel agents + chemotherapy
- Bevacizumab
- Vascular Endothelial Growth Factor (VEGF)
- Principles of angiogenesis
- Bevacizumab in NSCLC: not for everybody
- Randomized phase II trial of Paclitaxel/Carboplatin with/without Bevacizumab in NSCLC
- Hemorrhagic events
- Example of tumor cavitation in lung following treatment with chemotherapy and Bevacizumab
- Patient haracteristics
- Response rates
- Hematologic and non-hematologic toxicity
- Treatment related deaths
- Efficacy by gender and age
- NCCN pactice guidelines in oncology-v.2.2008
- AVAiL: phase III trial of Bevacizumab + Gemcitabine and Cisplatin in advanced non|squamous cell NSCLC
- Second line therapy for advanced NSCLC: the role of Bevacizumab
- Adjuvant therapy in NSCLC
- Can a broader range of patients be safely treated with Bevacizumab?
- Protocol AVF3744g: BRIDGE trial
- Bevacizumab in small cell lung cancer
- Other VEGF inhibitors
- Overall survival by histology
- Toxicity of small molecular agents
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Evans, T. (2009, January 6). Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2024, from https://doi.org/10.69645/SXGJ5687.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Tracey Evans has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer
A selection of talks on Cancer
Hide